• "Biotech where science and spirit meet..."
Skip to content

{ Category Archives: } COVID-19

Amazon kicks off new role as diagnostics provider by making COVID test available online

Amazon has already changed the way we shop and filled our homes with “smart” gadgets, and now, the tech giant is looking to change the way we manage our health, both in the face of a pandemic and beyond. Amid the launch of its own wellness-tracking smartwatch and the expansion of the Amazon Care telehealth service,…

DoorDash to stock COVID-19 test kits for home delivery

The people who bring you lunch can now also deliver a COVID-19 diagnostic test, as screening for the pandemic disease continues to become a more ubiquitous part of everyday life. DoorDash has partnered up with the home-testing companies Everlywell and Vault Health to make sample collection kits available on-demand through its app, alongside sandwiches, pizza…

Russia’s Sputnik V nabs first Twitter-verified vaccine handle, but is it PR or propaganda?

A blue check for Sputnik V—and a cautionary marketing tale for the pharma industry? The Russian-developed coronavirus vaccine nabbed verified status from Twitter last week, doubling down on its broadcasting wave of tweets, retweets and plenty of American-style attitude. But is the now-authenticated social media account a pharma influencer case study or a cautionary tale of disinformation? While…

Eli Lilly’s COVID-19 antibody shows it can prevent the disease. But will doctors use it?

Eli Lilly’s bamlanivimab was the first antibody drug the FDA authorized to treat COVID-19. Now, the Indianapolis pharma has data showing the therapy prevents symptomatic infections. The catch? The data are limited to long-term care facilities, where vaccination is now underway—and despite their utility, antibody thereapies are having a tough time catching on. Bamlanivimab cut the…

JPM: Regeneron execs say ‘it’s a problem’ how few COVID-19 patients are getting antibody treatments

To Regeneron, there’s no question about it: “We as a society have to do a much better job” of getting antibody therapies—such as the company’s own—to patients, R&D chief George Yancopoulos said Monday at the J.P. Morgan Healthcare Conference. Like Eli Lilly’s single-antibody treatment, Regeneron’s antibody cocktail bears an emergency use authorization in mild-to-moderate COVID-19 patients at…

Covid-19 roundup: Inovio enlists plasmid manufacturer to replace the one it’s in legal feud with; Cyberattacks spotted targeting vaccine distribution 

With its Phase II trial finally underway, Inovio has enlisted another key manufacturing partner to hit its goal of hundreds of millions of doses of its DNA vaccine — filling the role of a contract manufacturer it’s still in a legal standoff with. Japan’s Kaneka Eurogentec is tasked with plasmid production, for which Inovio has…

Is Sorrento Therapeutics Stock a Buy?

Back in May, Sorrento Therapeutics (NASDAQ:SRNE) captivated investor attention after it claimed the discovery of an antibody that can provide “100% inhibition” against COVID-19. In fact, the company’s senior vice president, Dr. Mark Brunswick, made the following statement in an interview by Fox News: “So, if we were approved [by the U.S. Food and Drug…

Trump Administration’s Operation Warp Speed Accelerates AstraZeneca COVID-19 Vaccine to be Available Beginning in October

Responding to President Trump’s call to develop 300 million doses of SARS-CoV-2 vaccine by January under Operation Warp Speed, the U.S. Department of Health and Human Services (HHS) and AstraZeneca are collaborating to make available at least 300 million doses of a coronavirus vaccine called AZD1222, with the first doses delivered as early as October…

A look at Inovio’s Philly local coronavirus vaccine-in-progress

Operation Warp Speed, the federal government’s multi-agency push to develop a COVID-19 vaccine, is promising to provide 300 million doses by January 2021. That means funding for several of the top candidates. Moderna, one of the leaders of the pack, is already in Phase III trials after creating its first vaccine in a record-breaking 42…

Celularity announces the activation of first California Clinical Trial Site following CIRM Grant Award to Advance Treatments for COVID-19

FLORHAM PARK, N.J., Aug. 5, 2020 /PRNewswire/ — Celularity today announced that it has been awarded a $750,000 COVID-19 Project grant by the California Institute for Regenerative Medicine (CIRM), one of the three clinical awards targeting the coronavirus. This grant will support California Institutions participating in the Phase I/II clinical trial of human placental hematopoietic stem cell derived natural killer (NK)…